The Blology of Prostate Cancer (BPC) Program at the Kimmel Cancer Center (KCC) is a new program that emanated from the former Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, and represents the section of the EHMAC that focused on prostate cancer. From 2007 to 2011, EMHAC increased the number of highly productive investigators studying either breast/gynecological malignancies or prostate/genitourinary cancers, allow^ing the strategic creation of the BPC program in 2011. During this same interval, the Greater Philadelphia Prostate Cancer Working Group was founded by new recruit Dr. Karen Knudsen, and served as a basis for development of the BPC and the associated consortium. The BPC program consists of 18 investigators from 10 departments and 3 institutions. The Program currently brings in $2.3 million/year in total costs from NCI grants and $4.1 million/year total peer-reviewed costs. Since 2007, the program produced 343 publications of which, 10% of publications were intra-programmatic, 43% were inter-programmatic, and 5% were both inter- and intra-programmatic. Dr. Karen E. Knudsen (Leader) is an accomplished investigator with expertise in basic and translational prostate cancer research. Dr. Gomella, the Co-Leader (TJU) of BPC, provides clinical expertise in genitourinary malignancies. Dr. Fatatis the Co-leader (Drexel University) of BPC is an accomplished physician scientist with expertise in cancer metastasis at the basic and clinical level. He will play a pivotal role integrating Drexel University and TJU cancer researchers in the BPC Program. The goals of the BPC program are to leverage the significant translational and clinical expertise in genitourinary oncology (most especially with regard to prostate cancer) with the intent to: delineate the mechanisms that underpin prostate cancer development and progression, identify novel means to treat advanced disease, and improve disease management by translating these findings into clinical trials. Studies within the program are directed at developing new strategies for effective detection,diagnosis,and cure.
Specific aims of this program are to;1. Develop new strategies for prevention, detection, and subtyping of early stage prostate malignancies;2. Define the impact of hormone action in malignant disease development and prostate cancer progression;3. Develop novel treatment strategies for prostate malignancies;4. Develop predictive markers for rational therapy delivery.
Prostate cancer remains the most frequently diagnosed malignancy and second leading cause of male cancer death in the United States. Dedicated to eradicating death and suffering from prostate cancer, the Biology of Prostate Cancer (BPC) program combines expert basic and clinical scientists who focus their studies on improving eariy detection and cancer prevention, and on uncovering new effective treatment of advanced disease.
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337|
|Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136|
|Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305|
|Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516|
|Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595|
|Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693|
|Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603|
|Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:|
|Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552|
Showing the most recent 10 out of 807 publications